Table 1 Characteristics of included studies.

From: The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis

Study

Country

Comparisons

Mean age (years)

Gender

(M/F)

Sample size

Duration of follow-up

Positive Helicobacter pylori test (%)

Bytzer15

Europe*

Rab 10 vs Pla

47/48

180/238

418

6 months

36/37

FASS16

USA

Dex 30 vs Dex 60 vs Pla

47.6/47.5/47.5

274/673

947

1 month

30.2/28.6/28.9

Kahrilas17

USA

Rab 20 vs Pla

43.1/44

85/176

261

1 month

32.6/30.3

Kinoshita20

Japan

Ome 10 vs Ome 20

41.7/48.2

18/19

37

1 month

29.4/30

Kinoshita19

Japan

Rab 5 vs Rab 10 vs Pla

46.3/46.8/49.7

128/157

285

1 month

38/42/48

Lind21

Denmark and Sweden

Ome 10 vs Ome 20 vs pla

49/50/51

206/303

509

1 month

/

Lind22

Denmark and Sweden

Ome 10 vs Ome 20 vs pla

51/52/48

179/245

424

6 months

/

Miner23

USA

Rab 10 vs Rab 20 vs Pla

44.4/45.5/46.1

77/126

203

1 month

26.6/35.3/39.7

Richter24

USA

Ome 10 vs Ome 20 vs pla

50/49.5/49.7

193/166

359

1 month

/

Richter25 L

USA

Lan 15 vs Lan 30 vs Pla

44.9/45.1/46.3

257/363

620

2 months

23.9/23.8/13.4

Talley26

Denmark, Finland, Norway and Sweden

Eso 20 vs Pla

49/49

191/151

342

6 months

38/33

Talley27

UK

Eso 20 vs Eso 40 vs Pla

48.4/48/48.2

328/393

721

6 months

35.8/30.7/39

Tan28

China

Eso 20 vs Pla

48.5/48.3

62/113

175

2 months

/

Uemura29

Japan

Ome 10 vs Ome 20 vs pla

44.4/43.8/42.4

143/138

281

1 month

38.5/52.7/45.7

Katz18 A

USA

Eso 20 vs Eso 40 vs Pla

47/47/46

143/225

368

1 month

37/39/29

Katz18 B

USA

Eso 20 vs Eso 40 vs Pla

46/45/47

126/223

349

1 month

43/30/38

  1. Rab 5: Rabeprazole 5 mg; Rab 10: Rabeprazole 10 mg; Rab 20: Rabeprazole 20 mg; Pla: Placebo; Dex 30: Dexlansoprazole 30 mg; Dex 60: Dexlansoprazole 60 mg; Ome 10: Omeprazole 10 mg; Ome 20: Omeprazole 20 mg; Lan 15: Lansoprazole 15 mg; Lan 30: Lansoprazole 30 mg; Eso 20: Esomeprazole 20 mg; Eso 40: Esomeprazole 40 mg.
  2. *Greece, Italy, the Netherlands, Spain, France, Portugal, Sweden, Denmark, Ireland, Belgium, United Kingdom, Russia, Poland, and Lithuania.
Back to article page